Prof. Dr. Baldur Sveinbjørnsson achieved a PhD degree at the Medical Faculty of the University of Tromsø with a focus on mechanisms and mediators behind immunomodulation of experimental tumors (1998). Since then, he has gained broad experience in preclinical oncology at the University of Tromsø and Karolinska Institutet Stockholm (Senior Scientist 2005-2009). He has been involved in the research activities of Lytix Biopharma since the beginning and has most recently led the company’s research activities as Chief Scientific Officer. He is also a visiting professor at the University of Tromsø. His research interests include oncolytic substances, preclinical models, immunotherapy, and drug development.